)
)
)
OmnigeniQ is pioneering a new class of biological intelligence. By combining quantum biophysics with advanced AI, we compute biological behaviour from first principles, making biology predictable and programmable. This is the foundation of the Virtual Biology frontier: an emerging trillion-dollar domain where biology becomes fully computable.
Year Founded
2024
Next catalyst (value inflection) update
OmnigeniQ developed a deterministic, physics-based compiler that converts genetic or molecular input into a 3-D model. It unifies quantum-level field mechanics with biological translation logic that lets us predict how a molecule will behave in its real hydrated, charged, and mechanical environment. We will unveil scientific and technical milestones that mark a major inflection point for computational biology and drug discovery. Attendees will be the first to see evidence of a world-first demonstration in deterministic protein computation performed entirely from physics, with no machine learning, no training data, no templates, and no external structural libraries. For the first time, we will reveal how our platform has achieved deterministic folding of a clinically significant human protein from first principles alone, and how this breakthrough validates the core engine driving our path toward a physics-true in silico human twin. We will also outline how deterministic computation can compress discovery timelines by 10–100×, eliminate costly trial-and-error cycles, and provide mechanistic clarity that dramatically reduces R&D risk.
Expected time of next catalyst update
Tuesday January 13th, 2:30pm Franciscan A (Ballroom Level), Hilton San Francisco - Union Square
City
Adelaide
Country
Australia
Company CEO or top company official
Jordana Blackman
Development Phase of Primary Product
Other/Not Applicable
Lead Product in Development
OmnigeniQ provides a deterministic, physics-based engine that gives drug developers a level of biological understanding that has never before been computationally accessible. Instead of relying on static structures, probabilistic AI, or noisy preclinical models, OmnigeniQ computes biological behaviour directly from physical laws—allowing researchers to see mechanisms, liabilities, and therapeutic opportunities long before entering the lab. For pharmaceutical and biotech teams, OmnigeniQ delivers mechanistic clarity in the earliest stages of discovery, enabling them to: • Identify viable targets earlier • Understand mechanism, toxicity, and off-target risks up front • Prioritise assets with far higher confidence • Reduce dependence on animal models and brute-force screening • Avoid costly late-stage failures • Generate transparent, NAM-aligned evidence regulators can trust Instead of making high-stakes decisions with incomplete insight, teams get a deterministic, reproducible model of how molecules and pathways actually behave in physiological conditions.
Number of Unlicensed Products
1
Therapeutic Area
Tools/Drug Development Support Tech
Website
https://omnigeniq.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
